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Historically, systemic self-inflammatory conditions were classified as either
autoinflammatory and caused by the innate immune system or autoimmune and driven
by adaptive immune responses. However, it became clear that reality is much more
complex and that autoimmune/inflammatory conditions range along an “inflammatory
spectrum” with primarily autoinflammatory vs. autoimmune conditions resembling
extremes at either end. Epigenetic modifications influence gene expression and alter
cellular functions without modifying the genomic sequence. Methylation of CpG DNA
dinucleotides and/or their hydroxymethylation, post-translational modifications to amino
termini of histone proteins, and non-coding RNA expression are main epigenetic events.
The pathophysiology of autoimmune/inflammatory diseases has been closely linked
with disease causing gene mutations (rare) or a combination of genetic susceptibility
and epigenetic modifications arising from exposure to the environment (more common).
Over recent years, progress has been made in understanding molecular mechanisms
involved in systemic inflammation and the contribution of innate and adaptive immune
responses. Epigenetic events have been identified as (i) central pathophysiological
factors in addition to genetic disease predisposition and (ii) as co-factors determining
clinical pictures and outcomes in individuals with monogenic disease. Thus, a complete
understanding of epigenetic contributors to autoimmune/inflammatory disease will result
in approaches to predict individual disease outcomes and the introduction of effective,
target-directed, and tolerable therapies. Here, we summarize recent findings that signify
the importance of epigenetic modifications in autoimmune/inflammatory disorders
along the inflammatory spectrum choosing three examples: the autoinflammatory
bone condition chronic nonbacterial osteomyelitis (CNO), the “mixed pattern” disorder
psoriasis, and the autoimmune disease systemic lupus erythematosus (SLE).
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INTRODUCTION
Autoimmune/inflammatory diseases are characterized by systemic or organ-specific inflammation
resulting in tissue damage (1). Historically, autoimmune/inflammatory conditions were
categorized into autoinflammatory vs. autoimmune disorders. Autoinflammatory disorders were
defined by systemic or organ specific inflammation that occurs in the absence of high-
titer autoantibodies and autoreactive lymphocytes. Autoimmune conditions, on the other
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hand, were classified as such disorders that are driven by the
adaptive immune system and therefore characterized by the
presence and pathophysiological involvement of autoantibodies
and/or self-reactive lymphocyte populations (2). More recently,
it became clear that the situation may be more complex and that
only few monogenic disorders, such as e.g., cryopyrin-associated
periodic syndromes (CAPS), primary type I interferonopathies,
and other “monogenic” disorders can clearly be classified as
primarily autoinflammatory in nature. This, however, can change
over the course of disease. Tissue damage frequently results in
cell death and subsequently the presentation of intracellular and
nuclear components to adaptive immune cells, their activation
and, as a consequence, in autoantibody production and/or
self-directed lymphocyte responses (2). Based on this and
the observation that some disorders initially show a mixed
immunological pattern (e.g., psoriasis) that drive inflammation,
the “inflammatory spectrum” has been proposed (3). Systemic
autoimmune/inflammatory conditions can be stratified along the
spectrum with monogenic autoinflammatory conditions at the
one and “classical” autoimmune conditions at the other end
of the spectrum. The paradigm of an inflammatory spectrum
also allows to consider autoimmune/inflammatory conditions as
dynamic processes in which molecular phenotypes can change
and define variable clinical phenotypes, outcomes, and treatment
responses (2–4).
Reflecting the constantly increasing number of known
autoimmune/inflammatory conditions, aforementioned inter-
individual variability in phenotypes, and outcomes (sometimes
even between patients with the same diagnosis and/or between
family members) (5), and the observation that initially distinct
disorders may move along the inflammatory spectrum
from e.g., a primarily autoinflammatory to an autoimmune
phenotype [this can e.g., happen over time in systemic JIA
and adult Still’s disease (6, 7)], the molecular pathophysiology
of autoimmune/inflammatory conditions is complex and
only partially understood. To our current understanding,
autoimmune/inflammatory diseases are based on monogenic
disease causes (rare) or complex genetic predisposition (more
common) that are subject to individual and environmental
influences that define disease expression and/or individual
phenotypes and outcomes (2, 4, 8–10). This becomes particularly
clear considering “classical” autoimmune disorders in which
genetically identical monozygotic twins can be discordant
regarding the development of autoimmune/inflammatory
conditions. Disease concordance rates between monozygotic
twins range between 13% in multiple sclerosis (MS) (11),
20% in psoriasis (12), 24% in type 1 diabetes (T1D) (13), and
14.3–40% in systemic lupus erythematosus (SLE) (14–16). These
observations resulted in the hypotheses that (i) disease-causing
single gene mutations in rare autoinflammatory disorders cause
disease-onset, but do not necessarily define individual outcomes,
and that (ii) genomic variants define disease susceptibility in
genetically complex disorders, but disease expression, individual
phenotypes, and outcomes are instigated and defined by
additional factors, including epigenetics (17).
Epigenetic events are gene regulatory mechanisms that
control the accessibility of chromatin to transcriptional
regulatory factors, thereby tuning gene expression without
changing the underlying DNA sequence (18). Epigenetic
events can be influenced by the environment, are dynamic but
also heritable and are in the end responsible for significant
variation between cells and tissues in one organism, independent
of the identical genotype between all diploid cells (19).
Epigenetic mechanisms include DNA methylation, post-
translational modifications to histone proteins, and non-coding
RNA expression.
DNA Methylation and DNA
Hydroxymethylation
The addition of a methyl group onto the 5′carbon position of
cytosine in cytosine-phosphate-guanosine (CpG) dinucleotides
can potently reduce accessibility to DNA for transcription
factors and RNA polymerases, and thereby repress transcription
(see Figure 1A). DNA methyltransferase (DNMT) enzymes are
responsible for maintaining methylation. DNA re-methylation
is essential during cell division to copy the epigenetic code to
the daughter cell generation, but also de novo methylation to
silence previously active genes plays a role in gene regulation.
DNMT1 and DNMT2 are responsible for re-methylation of DNA
during cell division (20, 21), while DNMT3a and 3b introduce
new methyl groups to previously unmethylated DNA (22).
However, the situation may be more complex and discrimination
between maintenance and de novoDNMTs may be an unjustified
oversimplification; e.g., DNMT1 is indeed involved in both
methylation of daughter strands during cell division and de novo
methylation of regulatory regions (10).
DNAmethylation can be changed by Ten-eleven translocation
methylcytosine dioxygenase (TET) proteins which convert
methyl- to hydroxymethylcytosines (23). Thus, DNA
hydroxymethylation is considered an intermediate on the
way from heavy DNA methylation of transcriptionally repressed
genes to a demethylated state at open and transcriptionally active
chromatin (24). Hydroxymethylated CpG sites are protected
from DNMTs and therefore from DNA methylation (25). The
absence of TET proteins and therefore inhibition of hydroxyl-
conversion, does, however, not necessarily result in higher DNA
methylation levels. Thus, hydroxymethylation is considered an
independent and also stable epigenetic event (23). Indeed, DNA
hydroxymethylation is considered an activating epigenetic mark
and coincides with increased gene expression when compared to
methylated DNA (24) (see Figure 1A).
Histone Modifications
To three-dimensionally organize its composition and
accessibility to the transcriptional complex, DNA is wrapped
around histone protein complexes, octamers consisting of
two copies of each histones H2A, H2B, H3, and H4. Histone
proteins can be modified at their N-terminal amino residues,
which mediates changes in their electrical charge and thereby
defines accessibility of chromatin to the transcriptional complex
(8). A number of histone modifications has been reported,
including methylation, citrullination, or acetylation (e.g. see
Figure 1B). Examples for “silencing” histone modifications
include histone 3 lysine 9 di-methylation (H3K9me2), H3K9
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FIGURE 1 | Epigenetic modifications regulate gene transcription and translation. (A) DNA methyltransferase (DNMT) enzymes maintain or generate (de novo) DNA
methylation at CpG dinucleotides. DNA methylation confers repression of gene expression through reduced transcription factor accessibility. DNA Hydroxymethylation
is achieved through oxidation of methylated CpG DNA and mediated by Ten-eleven translocation methylcytosine dioxygenase (TET) proteins. DNA hydroxymethylation
defines an “open” chromatin structure which allows for gene transcription (similar to unmethylated CpG DNA). (B) Histone methyltransferases (HMT) can add (one to
three) methyl groups to histone amino termini. Depending on the exact molecular location and the degree of histone methylation, this can lead to chromatin
compaction or decompaction. Methylation of histone H3 at lysine 27 (H3K27) will lead to chromatin compaction and transcriptional repression, while methylation at
H3 lysine 4 (H3K4) and H3K36 mediates “opening” and increases transcription. Histone demethylases (HDM) can counteract this by removing the methyl groups.
Histone acetylation is mediated by histone acetyltransferases (HAT) and can be reversed by histone deacetylases (HDAC). Histone acetylation is associated with
chromatin decompaction and transcription of genes. (C) The transcription of non-coding RNA from intergenic or intronic regions can promote coding mRNA
transcription by providing an open chromatin formation. (D) Short micro-RNAs (miRNA) can mediate transcriptional repression through inhibition of the ribosome when
binding to the 3’UTR region of mRNAs. Furthermore, miRNAs can induce degradation of the mRNA through initiation of the miRISC complex.
tri-methylation (H3K9me3), or H3K27me3, whereas histone 4
lysine 16 acetylation (H4K16ac), H3K4me3, H3K18ac, H3K27ac,
or H3K56ac are markers of active transcription (10, 26–28).
Of note, histone modifications, and CpG methylation
are connected through methyl-CpG-binding proteins (MBD)
(29). These proteins recruit both histone deacetylases and
methyltransferases which cause silencing through histone
modification (29, 30). Moreover, histone tail modifications can
allow or prohibit binding of DNMT3 (31).
Non-coding RNAs
Non-coding RNAs can be derived from both introns and
intergenic regions. They include microRNA, short interfering
RNA, and long non-coding RNA among others. Non-coding
transcripts in intergenic regions regulate the chromatin
accessibility during transcription by maintaining an open
chromatin structure (32) (see Figure 1C). Furthermore,
intergenic transcription may mediate interactions between
promoter regions and distal enhancers, sometimes between
chromosomes (33). While these concepts are promising and
of potentially central interest in the context of dysregulated
inflammatory responses and autoimmune disease, data on the
involvement of long non-coding RNA expression in immune
homeostasis is incompletely understood and remains subject
to speculation.
More scientific focus has been put on deciphering the effects of
microRNAs (miRNA), which contribute heavily to fine regulation
of gene expression. While discussed controversially by some
authors, miRNAs fulfill the definition of epigenetic events (define
cellular phenotypes through the regulation of gene expression
while not affecting the underlying DNA sequence, they are
heritable but also inducible and reversible) (9). Micro-RNAs are
21–23 bases long and target mRNAsmainly at the 3′ untranslated
region (3′UTR). Interaction with mRNA leads to cleavage and
degradation, thereby preventing translation (see Figure 1D) and
inducing translational arrest (34). On top of being considered
an epigenetic event, miRNAs regulate other epigenetic events,
e.g., through targeting DNMTs and thereby mediating DNA
hypomethylation. Micro RNAs-29,−29b, and−143 interfere
with the expression of DNMT3a and−3b and indirectly
also DNMT1 (35–37). Currently, ∼2,000 human miRNAs
have been described (38). The involvement of miRNAs in
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human disease has been established, including inflammatory
disease, and cancer. Some miRNAs have multiple targets and
functions and can therefore be seen as “multivalent” agents
that regulate the expression of several proteins and multiple
miRNAs can interfere with the expression of single genes (38).
Variations of miRNA expression between ethnic populations
(which also exhibit variable risk, phenotypes, and outcomes in
autoimmune/inflammatory disease) have made them interesting
candidates in the search for molecular pathomechanisms
in inflammatory conditions. Potential importance in the
pathophysiology of autoimmune disease is suggested by their
involvement in the regulation of up to 80% of human
genes (39).
In the following, we will discuss the contribution of
epigenetic alterations to systemic autoimmune/inflammatory
disorders along the inflammatory spectrum choosing three
examples: (i) inflammasome-associated autoinflammatory
diseases (namely cryopyrin-associated periodic syndromes;
CAPS and chronic nonbacterial osteomyelitis; CNO),
(ii) the mixed-pattern disease psoriasis, and (iii) the
“prototypical” autoimmune disorder Systemic Lupus
Erythematosus (SLE). This work is not an all-inclusive review
of the literature available, but rather aims at introducing
concepts, and mechanisms behind epigenetic events and their





Autoinflammatory disorders are characterized by systemic or
organ specific inflammation in the absence of autoreactive
lymphocytes and high-titer autoantibodies. Among the first
autoinflammatory conditions genetically identified were
inflammasome-associated disorders that are characterized by
increased activation of the NLRP3 inflammasome, a cytoplasmic
multi-protein complex that assembles in response to contact
with “danger signals” and mediates the activation of caspase-1
(40). Caspase-1 cleaves inactive pre-IL-1β that is stored in the
cytoplasm into its active form IL-1β, which is then released
from the cell and induces strong down-stream pro-inflammatory
responses (41, 42). Furthermore, caspase-1 mediated cleavage
of gasdermin D (a pore forming protein) leads to inflammatory
cell death which is referred to as pyroptosis (43). Prototypical
representatives of this group are rare monogenic conditions
following “Mendelian” traits of inheritance and include (but
are not limited to) the TNF receptor-associated periodic
syndrome (TRAPS), familial Mediterranean fever (FMF), and
CAPS (44). These conditions (at least at disease-onset) lack
classical autoimmune features (autoantibodies, autoreactive B
and T cells) that are observed in autoimmune diseases, such
as SLE.
Mutations in the cytoplasmic danger sensor NLRP3 cause
CAPS. Cryopyrin-associated periodic syndromes cover a
spectrum of disorders with different severity, including the least
severe form familial cold autoinflammatory syndrome (FCAS),
Muckle-Wells syndrome, and the most severe Neonatal-onset
Multisystem Inflammatory Disease (NOMID). All of these
can be caused by identical mutations in the NLRP3 gene
and it remains currently unknown why some patients (even
within one family) develop FCAS while others experience
NOMID. CAPS patients display spontaneous activation
of the NLRP3 inflammasome and increased IL-1β release
which clinically manifests with skin, joint, and central
nervous system inflammatory disease (45). Of note, only
about 50–60% of patients with NOMID exhibit mutations
in the NLRP3 gene leaving the rest currently unexplained.
Low-level mosaicism in “mutation-negative” CAPS patients
can be detected using new generation deep sequencing
techniques and explain some additional cases. However,
unexplained cases with unknown molecular pathophysiology
remain (46).
Epigenetic mechanisms are involved in the pathophysiology
of CAPS. Lesional and non-lesional skin biopsies from
CAPS patients unveiled down-regulation of 813 genes which
included histone proteins e.g., HIST2H2AC, histone modifying
genes e.g., HDAC1, HDAC2, SUMO1, and genes connected
to methylated DNA e.g., MBD2 (47). Histone deacetylase
enzymes (HDACs) remove acetyl groups from amino-termini
of histone proteins and therefore affect chromatin arrangement
(48). The suggestion that CpG DNA methylation may be
altered in CAPS coincides with changes in DNA methylation
observed in monocytes from CAPS patients as compared
to healthy controls. While the methylation status of IL1B,
NLRC5, PYCARD, AIM2, and CASP1 remained the same in
healthy controls after stimulation, CAPS patients show strong
demethylation of those genes in monocytes and monocyte-
derived macrophages in response to IL-1β (49). It is worth
mentioning that IL-1 blocking treatment reversed these effects,
indicating that increased IL-1β activation, and release may
prime DNA demethylation which could maintain and/or
amplify inflammation.
However, data on the involvement of epigenetic events in
the pathophysiology of CAPS remain somewhat controversial.
While Aubert et al. described downregulation of transcripts,
Vento-Tormo et al. (49) described DNA demethylation at
inflammasome-associated genes, which suggests increased gene
expression. However, the latter group has investigated only a
small group of genes which were not included in the study
of Aubert et al. This indeed suggests that DNA methylation
(and other epigenetic events) are complex, tissue-, gene-, and
element-specific and may vary significantly between disorders
and individuals. Furthermore, it is important to note that, while
a number of genes are down-regulated in CAPS, inflammasome-
related genes [which exhibit reduced DNA methylation in the
study by Vento-Tormo et al. (49)] are upregulated, underscoring
their role as main drivers in the disease. Additionally,
transcriptomics data from Aubert et al. showed that miRNAs are
generally upregulated in lesions of NOMID patients compared
to non-lesional skin or healthy controls, which may (at least)
partially be responsible for decreased mRNA detection in the
same study (47).
Frontiers in Immunology | www.frontiersin.org 4 July 2019 | Volume 10 | Article 1525
Surace and Hedrich Epigenetics in Autoimmune/Inflammatory Disease
Several miRNAs upregulated in CAPS target NLRP3 and
associated molecules. The NLRP3 sensor component of the
inflammasome can be regulated by miRNAs, including miR-
7, miR-20, miR-133b, or miR-223 (50). Binding of these
miRNAs to 3’UTR regions leads to reduced NLRP3 expression
and IL-1β release (51). Both miR-7 and miR-133b are
increased in non-lesional skin biopsies from NOMID patients
as compared to healthy controls. Since this was even more
pronounced in lesional skin biopsies, authors argue that
miRNA expression may represent a regulatory mechanism
counteracting inflammasome activation, which, however, may
not be sufficient in pathologically over-active situations, such
as CAPS (47). miR-203 is another miRNA upregulated in
skin lesions of CAPS patients which exerts pro-inflammatory
effects in the skin. It downregulates the suppressor of cytokine
signaling 3 (SOCS-3) by binding to the 3’UTR region of
its mRNA (52). SOCS-3 protein is important to attenuate
IL-6 mediated activation of the transcription factors signal
transducer and activator of transcription (STAT)3 and STAT1
and inhibition of this negative feedback loop may allow
for prolonged inflammatory activity (53). This is in contrast
to findings reported by Aubert et al. who determined (not
statically significant) increased SOCS-3 mRNA expression in
lesional skin biopsies from CAPS patients. On the other
hand, lower levels of SOCS-3 mediated through increased
levels of miR-203 may allow for increased STAT3 activation
and subsequent IL-6 signaling, which is a hallmark of
CAPS/NOMID (47).
Taken together, though incompletely understood,
epigenetic mechanisms may play an essential role during
disease progression in CAPS by increasing the production
of inflammasome components. Epigenetic events may,
at least partially, explain inter-individual differences in
disease severity within families and promise potential as
future disease biomarkers and/or targets for individualized
therapeutic interventions.
Another inflammasome-associated autoinflammatory disease
is CNO. It mostly affects children and adolescents and is
characterized by spontaneous bone inflammation that can
result in pain, bone deformity and even fractures. While
some patients exhibit monofocal and sometimes timely limited
and monophasic disease, others develop chronically active or
recurrent bone inflammation at multiple sites. In such cases,
the term chronic recurrent multifocal osteomyelitis (CRMO) is
used (54). A subset of patients exhibits additional inflammatory
symptoms, including psoriasis, and palmoplantar pustulosis,
severe acne and/or inflammatory bowel disease. While the
exact molecular pathophysiology of CNO remains unclear,
it became apparent that reduced expression of immune-
regulatory cytokines IL-10 and IL-19 as well as increased NRLP3
inflammasome assembly are centrally involved (55, 56). Despite
IL10 promoter polymorphisms that are meant to result in
increased IL-10 expression, patients with CNO exhibit reduced
IL-10 expression in monocytes in response to Toll-like receptor
(TLR-)4 activation with lipopolysaccharide (LPS). This has been
linked with failure to activate mitogen activated protein kinases
(MAPK) extracellular signal regulated kinase (ERK)1 and 2 in
monocytes. This in turn results in reduced phosphorylation of
histone 3 serine 10 (H3S10P) at the IL10 and IL19 promoter
regions (57). IL-10 and its homolog IL-19 are immune regulatory
cytokines that undergo regulation through epigenetic events. For
example, it has been described, that phosphorylation of histone
H3 (mouse derivedmacrophages) allows for increased expression
of IL-10 (58). Furthermore, strongly correlated tissue/cell specific
co-regulation has been described for IL10 and IL19. Dependent
on the cell type, variable CpG sites are methylated contributing
to differential expression of cytokines (59–61). In addition
to effects on epigenetic marks in monocytes from CNO
patients, reduced ERK1/2 activation prohibits activation of the
transcriptional regulatory factor signaling protein (Sp-)1 which
results in reduced nuclear translocation and recruitment to
IL10 and IL19 (56). Together, reduced H3S10P (an activating
epigenetic mark) and impaired Sp-1 phosphorylation result
in altered IL-10 and IL-19 expression in monocytes from
CNO patients (57).
IL10, IL19, and the pro-inflammatory IL-10 family cytokine
IL20 are located in the IL10 cluster on chromosome 1 (33).
In contrast to IL-10 and IL-19, the pro-inflammatory cytokine
IL-20 is expressed at increased levels in monocytes from
CNO patients in response to TLR-4 stimulation with LPS.
While IL-20 expression is not dependent on Sp-1, reduced
DNA methylation at the IL20 promoter may favor gene
expression. Of note, both the IL10 and IL19 promoters show no
difference in CpG DNA methylation between CNO patients and
healthy controls (55). This underscores the complex interplay
between epigenetic modifications and effects of alterations to
their composition.
Reduced expression of IL-10 and IL-19 contribute to
inflammation by allowing increased expression of inflammasome
components and inflammasome assembly resulting in IL-1β
secretion (55, 62). As also suggested for CAPS by Vento-Tormo
et al. (49), increased expression of inflammasome components
can similarly be linked to reduced DNA methylation at genes
encoding for inflammasome components (NLRP3 and PYCARD)
in CNO monocytes (62). Whether DNA demethylation is
a result of reduced expression of immune-regulatory IL-
10 and IL-19 remains elusive. Another possible contributor
to DNA demethylation may be the aforementioned reduced
activation of ERK1/2 in monocytes from CNO patients (57).
Indeed, DNA demethylation of T cells from SLE patients
is a result of reduced MAPK activation, which centrally
contributes to the pro-inflammatory effector phenotype of these
cells (49, 50).
Taken together, these observations strongly suggest a
pathophysiological (CNO, CAPS) or disease-amplifying or
modifying (CAPS) role for epigenetic events in inflammasome-
associated autoinflammatory conditions (summarized in
Figure 2). This makes epigenetic alterations promising
candidates in the search for biomarkers for individual outcomes,
and/or targets for disease-modifying interventions.
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FIGURE 2 | Monocytes from CNO/CRMO patients are epigenetically primed for inflammation. (A) In response to TLR4 activation (with lipopolysaccharide; LPS)
monocytes from healthy individuals phosphorylate mitogen activated protein kinases (MAPK) extracellular signal reactive kinases (ERK)1 and 2. Kinases activate the
transcriptional regulatory factor signaling protein Sp-1, which results in its translocation into the nucleus. Furthermore, ERK1/2 contribute to histone H3
phosphorylation at serine residue 10 (H3S10) resulting in an open chromatin structure at IL10 and IL19. These events together result in trans-activation of IL10 and
IL19. Immune regulatory cytokine expression (IL-10 and IL-19) negatively affect the expression of the pro-inflammatory IL10 cytokine family member IL-20.
Furthermore, the IL20 promoter is controlled by CpG DNA methylation. Inflammasomes are multi-protein complexes that become activated in response to “danger
signals.” Furthermore, the expression of inflammasome components (NLRP3 and ASC/PYCARD) is regulated by epigenetic events. Promotors of NLRP3 and
PYCARD are controlled by CpG DNA methylation. (B) In monocytes from CNO/CRMO patients, ERK1/2 activation in response to LPS stimulation is impaired which
results in reduced Sp-1 activation and nuclear shuttling, and decreased H3S10 phosphorylation at IL10 and IL19 resulting in impaired gene expression. Reduced
levels of immune regulatory cytokine expression allows for higher expression of the pro-inflammatory cytokine IL-20. Furthermore, impaired IL-10 and IL-19 expression
promoted expression of inflammasome components, and reduced CpG DNA methylation of the PYCARD and NLRP3 genes further increase pro-inflammatory
molecule expression. Thus, epigenetic events are involved in the molecular pathophysiology of CNO/CRMO.
EPIGENETIC EVENTS IN THE MIXED
PATTERN DISEASE PSORIASIS
Psoriasis is a systemic autoimmune/inflammatory condition
that manifests with skin involvement. A subset of patients
develops additional symptoms and organ involvement, such as
arthritis. Psoriatic arthritis (PsA) is characterized by sometimes
treatment resistant, chronic progressive and destructive arthritis.
Approximately 0.27% of patients with adult-onset psoriasis
will develop PsA per year (63). Considering the inflammatory
spectrum, psoriasis exhibits features of a mixed-pattern disease
based on stage and phenotype specific involvement of mediators
of innate and/or adaptive immune effectors. Especially in
early stages of the disease, but also during flares, the
innate immune system (neutrophils, monocytes/macrophages,
mast cells, and dendritic cells) is heavily involved in skin
infiltrates. At this stage, pro-inflammatory molecules including
IL-1β, TNF-α, and Interferon (IFN)-γ are key drivers of
inflammation (64). The innate molecular caspase recruitment
domain family member (CARD)14 resembles a key element
linking innate and adaptive immune mechanisms. Variants
in CARD14/PSORS2 are associated with familial (mutations)
and multifactorial (nucleotide polymorphisms) psoriasis (65,
66). Genetic variants contribute to the expression of pro-
inflammatory cytokines including TNF-α, IL-6, and IL-8, colony
stimulating factor (CSF)2 and matrix metallopeptidase (MMP)9
among others. This is an effect of increased NFκB signaling (66),
subsequently increased pro-inflammatory molecule expression
and the attraction of immune cells e.g., neutrophils through IL-
8 (67). Furthermore, the mixed pattern character of psoriasis
involves the presence of autoimmune features and the presence
and activation of the adaptive immune cells. Effector Th17 cells
are implicated in psoriasis and therapeutic targeting of IL-17
can alleviate symptoms (68). In later stages of psoriasis, effector
Th1 lymphocytes play an increasing role in the disease (64). Th1
cells produce pro-inflammatory cytokines including IL-2 and
IFN-γ. Effector T cell populations are believed to be a product
of type I interferon expression (IFN-α, IFN-β) derived from
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plasmocytoid dendritic cells (69). Indeed, IFN-γ is increased in
psoriatic plaques and treatment of other diseases with IFN-γ can
trigger psoriasis and psoriatic arthritis or induce flares (69, 70).
Epigenetic Changes in Immune Cells of
Psoriasis Patients
DNA methylation plays a role in promoting the pro-
inflammatory immune cell phenotype of psoriasis. Peripheral
blood mononuclear cells (PBMC) from patients with chronic
plaque psoriasis show significantly reduced levels of DNA
methylation across the genome (71). In line with these
observations, CD4+ T cells from psoriasis patient’s exhibit
reduced DNA methylation at promoter regions of genes on all
chromosomes (72). Recently, Brandt et al. reported reduced
DNA methylation at a distal enhancer element of the IFNG gene
(encoding for interferon-γ) in effector CD4−CD8−CD3+TCR+
(“double negative”; DN) T cells (73). Furthermore, authors
demonstrated that DN effector T cell infiltrate inflamed tissues
and may therefore contribute to inflammation and damage.
Indeed, increased IFN-γ expression in DN T cells may be of
pathophysiological relevance, since plaques of psoriasis patients
exhibit strongly Th1 driven skin inflammation (74). In contrast
to these observations in PBMCs and total CD4+ T cells, naïve
CD4+ T cells from psoriasis patients exhibit methylation profiles
that are mostly comparable to healthy controls (75).
Currently, studies investigating histone modification in
immune cells from psoriasis patients are sparse. One study,
investigating histone marks in PBMCs from psoriasis patients
delivered reduced levels of histone H3 and H4 acetylation
and increased H3K4 methylation (76). Histone methylation
and acetylation were not measured at specific genes, but as
a global marker within all PBMCs and did not decipher
between specific methylation or acetylation patterns (e.g., mono-
or trimethylated) or between specific loci on chromosomes.
Global histone acetylation and methylation patterns were
similar in PBMCs from psoriasis and PsA patients. Of note,
while H3K27 methylation did not differ between healthy
controls and untreated psoriatic disease patients, there was
a significant increase in this histone marker after treatment,
only for patients who responded to biologics. In contrast,
non-responders had no change in H3K27 methylation after
treatment compared to before treatment. In psoriasis patients,
excluding those with arthritis, reduction in H3K4 methylation
after 3 months of treatment associated with treatment response
(76). Of note, H3K27 demethylation in CD4+ T cells is
involved in effector T cell generation in autoimmune disease
(77) and drives Th17 differentiation (78). Thus, increased
H3K27 methylation may contribute to immune modulation
and disease control in treatment responders. This suggests
that H3 and H4 acetylation as well as H3K4 methylation
may be utilized as future biomarkers for psoriasis, and that
H3K27me3 may have potential in the search for biomarkers of
treatment response.
Indeed, Th17 phenotypes appear to be central to skin
inflammation and tissue damage in psoriasis. An imbalance
between CD4+ Tregs and Th17 cells has been described in
psoriasis (79). However, IL-17A production is not limited
to CD4+ T helper subsets. Also DN T cells produce this
inflammatory cytokine and (as mentioned above) infiltrate the
skin of patients with plaque psoriasis (80). In psoriasis, DN
T cells are characterized by increased surface expression of
the programmed cell death 1 (PD1) co-receptor, a regulatory
“immune checkpoint” that is involved in the termination of
inflammatory responses and immune homeostasis (73, 81).
Furthermore, DN T cells are incapable of proliferation, which
may be a regulatory response to their self-reactive nature or a
reflection of their over-activated and/or terminal differentiation
state. While, no data on IL-17 expression from DN T cells
in psoriasis has been published yet, aforementioned reduced
CpG DNA methylation of a distal enhancer element of IFNG
underscores their effector character and potential involvement in
psoriasis (73).
In addition to DNA methylation and histone modifications,
non-coding RNAs are involved in the imbalance between
regulatory and effector T cells in psoriasis. The expression of
miR-210 is increased in CD4+ T cells from psoriasis patients and
negatively affects FOXP3 expression, thereby inhibiting immune
regulatory functions (82).
Though associated with poor outcomes, the molecular
pathophysiology of PsA is largely unstudied and few data exist on
the involvement of epigenetics. One study investigated miRNA
profiles of PBMCs from PsA patients with inactive or active
disease (83). While 22 miRNAs were differentially expressed in
PBMCs from active patients, ten were specific to inactive, and 12
were specific to PsA independent of disease status. Investigation
of the role of differentially expressed miRNAs may contribute
to a better understanding of the molecular pathophysiology
of PsA. Interestingly, downregulated miRNAs in PBMCs from
patients with active disease for example would target SPP1 and
TNF (83). SPP1 encodes for osteopontin, a protein involved in
bone remodeling, a neutrophil chemoattractant and a facilitator
of T cell activation (84). TNF-α is a potent pro-inflammatory
cytokine usually associated with innate immune responses. This
underscores the activation of innate and adaptive immune
responses in psoriasis and psoriatic arthritis, and suggests that
non-coding RNAs are centrally involved in the pathophysiology
and accrual of damage in PsA (83).
Though research strongly focuses on the involvement of
adaptive immune responses in the pathophysiology of psoriasis,
the importance of the innate immune system, especially in
early stages should not be neglected [as described above (85)].
The pathophysiological significance of these is underscored
by the associations of genetic variants in innate immune
response related genes with psoriasis. Polymorphisms in
inflammasome and NFκB pathway associated genes, such as
CARD14, NLRP1, and NLRP3, increase the individual’s risk to
develop psoriasis (65, 85–87). Importance of the inflammasome
and the innate immune system shown in genetic studies
is in contrast to the current lack of epigenetic research
about them.
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Epigenetic Changes in Skin Cells From
Psoriasis Patients
Psoriasis is characterized by variable clinical pictures and
disease outcomes. Thus, it is not surprising that more
recently preliminary data became available indicating a role
of non-immune cells orchestrating and directing self-reactive
immune responses in psoriasis (88). Indeed, the interplay
between immune and stroma cells may contribute to a better
understanding of why certain organ system but not others are
affected in individual patients.
Affected skin collected from psoriasis patients exhibits
globally reduced levels of DNA methylation (71). Another study
demonstrated that skin biopsies from psoriasis patients differ in
DNA methylation of over 1000 CpG sites when compared to
skin from healthy individuals, while <30 CpGs differ regarding
their methylation status between affected and unaffected skin
from patients (89). Comparing unaffected skin from patients
to skin obtained from healthy individuals, only 15 CpG sites
exhibited differential DNA methylation. While a large number
of regions did not show significant differences, their methylation
levels ranged between the levels detected in healthy and affected
psoriatic skin. Genes with reduced DNA methylation include
GALR1, GPR26, ZNF454, ZNF540, NEF3, RGS7, MLF1, and
NRIP2, none of which, however, are known to functionally relate
to immune activation or autoimmune/inflammatory disease
(89). Only the hypomethylated MLF1 gene had previously been
reported to be expressed at higher levels in psoriasis. However,
immunological functions have not been suggested (90). Another
gene that is differentially methylated in psoriasis patients
could be of significant interest. PDCD1LG2, hypermethylated
in non-lesional skin of psoriasis patients when compared to
healthy controls (89). It encodes for PD1 Ligand 2, a ligand
for the aforementioned PD1 surface co-receptor which is
elevated on effector DN T cells (73). While the aforementioned
alterations to DNA methylation in skin cells are intriguing,
no data on mechanisms involved are currently available. Thus,
it is at least possible that disease-associated changes in DNA
methylation may be due to the infiltration of immune cells and
chronic inflammation rather than primarily responsible for skin
involvement and damage (71).
Data on altered histone modifications of skin cells in psoriasis
and their involvement in the pathophysiology are even sparser.
Lesional skin biopsies from psoriasis patients show increased
expression of HDAC1 when compared to controls (91). Besides
the findings of Tovar-Castillo et al. (91), hypomethylation of
the HDAC1 gene has also been described in affected psoriatic
skin compared to healthy controls (89). This suggests reduced
histone acetylation, which, however, was not investigated in
this study. Inhibition of HDAC proteins results in reduced
IL-17 production and the promotion of regulatory T cell
phenotypes (79). Increased expression of HDAC1 and IL-17
in psoriasis suggests that HDAC1 may be a suitable target of
future therapeutic interventions. However, currently, “epigenetic
treatments” with HDAC inhibition remain a controversial topic
(92), since (i) the primary involvement of HDACs in psoriasis is
not sufficiently proven, and (ii) currently available agents globally
inhibit HDAC activity and may cause significant and severe
treatment-associated side effects.
Expression profiles of non-coding RNAs show similarities
between inflammatory skin conditions. Psoriasis and atopic
eczema share altered expression of ten miRNAs that are not
expressed in the skin of healthy controls, five of which are
increased (miR-20a,-146a,-17.5p,-21, and-106) and five of which
are decreased (miR-122a,-133a,-133b,-326, and-215) (52). Exact
targets and downstream effects are not fully understood for many
of those miRNAs, at least for miR-21 it has been suggested that
it contributes to the increased presence of T cells in psoriatic
skin lesions through the suppression of apoptosis. Mechanisms
behind this, however, remain to be investigated (93). Increased
expression of miR-203 in keratinocytes from psoriasis patients
inhibits SOCS3 (as described above for CAPS patients) (52). As
a consequence, reduced SOCS3 expression leads to increased
activation of STAT3, which favors pro-inflammatory cytokine
expression (including IL-17A) (94).
In addition to the adaptive immune system and processes
involved in keratinocyte regulation, also innate immune
responses are dysregulated in psoriasis. They contribute to
the pathophysiology of “innate forms” or psoriasis and/or
disease flares in plaque psoriasis. miR-31, is overexpressed
in keratinocytes from skin lesions of psoriasis patients. It
contributes to the activation of NFκB, thereby inducing the
production of early mediators of inflammation in psoriasis,
namely IL-1β, CXCL1,-5, and-8. These cytokines are produced
in human keratinocytes in the presence of TNF-α and inhibition
of miR-31 reduces mRNA and protein expression of CXCL1,-
5, and-8 (IL-1β data only available for the mRNA level). The
direct target of miR-31 is serine/threonine kinase 40 which is
responsible for dampening NFκB signaling, thereby reducing
inflammatory cytokines such as CXCL1,-5,-8, and IL-1β (95).
These effectormolecules contribute to the chemotaxis of immune
cells, and local as well as systemic inflammation (2, 67). Thus,
miRNA-31 links innate and adaptive mechanisms in the mixed
pattern disease psoriasis. Another example for increased innate
immune activation in psoriatic skin is the increased expression
of caspase 1 and IL-1β mRNA, and AIM2 inflammasome
activation (96, 97).
Additional evidence for the involvement of miRNAs in
pathological activation of innate immune responses in psoriasis
comes from animal models. The imiquimodmodel of psoriasis in
mice is characterized by increased protein expression of NLRP3
that positively correlated with miR-155 expression in skin lesions
when comparted to unaffected skin. Overexpression of miR-155
in HaCaT keratinocytes results in increased NLRP3 and caspase-
1 expression in response to priming with lipopolysaccharide.
Authors concluded that this indicates positive effects of miRNA-
155 on inflammasome activity and that this mechanism may
centrally be involved in innate immune activation in psoriatic
skin (98).
The involvement of epigenetic changes in keratinocytes are
not limited to immune dysregulation, but also involved in
the induction of keratinocyte proliferation. Reduced miR-125b
expression in epidermal layers of psoriasis patients correlates
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FIGURE 3 | Epigenetics orchestrating interactions between immune and stroma cells in psoriasis. Increased expression of miR-210 in CD4+ T cells from psoriasis
patients reduces the expression of the immune regulatory molecule FOXP3. Together with increased histone deacetylase (HDAC) levels that contribute to increased
pro-inflammatory cytokine expression (particularly IL-17A), this leads to an imbalance between effector T cells (Th17 cell) and regulatory T cells. Effector
CD3+CD4−CD8− “double negative” (DN) T cells in psoriasis patients are epigenetically primed for IFN-γ expression through decreased CpG DNA methylation at a
distal enhancer element of the IFNG gene. Keratinocytes from psoriasis patients exhibit elevated miR-203 expression which results in reduced expression of SOCS3,
a negative regulator of STAT3 signaling. This contributes to increased STAT3 phosphorylation (activation) and subsequently increases pro-inflammatory cytokine
expression and effector T cell differentiation. Expression of miR-31 in keratinocytes contributes to the activation of NFκB and subsequent production of IL-1β,
CXCL1,-5 and-8. Elevated levels of miR-155 induce AIM2 and NLRP3 inflammasome activation through unknown mechanisms which results in enhanced
IL-1β release.
with increased proliferation. This may be pathophysiologically
meaningful, since miR-125b can suppress fibroblast growth
factor receptor 2 (FGFR2), a protein that stimulates keratinocyte
proliferation. Thus, reduced miR-125b can no longer sufficiently
control proliferation of keratinocytes contributing to psoriasis
typical hyperkeratosis (99).
Taken together, we are only beginning to understand
the complex involvement of epigenetic events (see Figure 3),
including DNA methylation, histone modifications and non-
coding RNA expression in the mixed-pattern disease psoriasis
and their involvement in the molecular pathophysiology,
organ pattern, and disease progression. Even less is known
about mechanisms underlying epigenetic events and which
epigenetic marks are indeed disease-causing (likely T cell marks
promoting effector cytokine expression) rather than effects of
chronic inflammation (e.g., global DNA demethylation in skin
lesions). However, current preliminary evidence is promising and
warrants future studies which will deliver molecular mechanisms
that may serve as biomarkers and therapeutic targets.
SYSTEMIC LUPUS ERYTHEMATOSUS
The systemic autoimmune/inflammatory condition SLE is
frequently considered an archetypal autoimmune disease based
on the presence of autoantibodies and autoreactive lymphocytes.
SLE is characterized by its highly complex pathophysiology
and, as a result of it, a wide range of symptoms and strong
inter-individual variation, which complicates the diagnosis and
treatment of this debilitating disease (4, 100, 101). However, not
all patients with the diagnosis SLE (based on the clinical picture
and the ACR classification criteria) indeed experience “classic”
autoimmune disease. About 1–4% of all patients with SLE have
monogenic conditions that are characterized by pronounced type
I interferon responses, including complement deficiencies, and
primary type I interferonopathies, which (at least at disease onset)
much better fit the criteria of autoinflammatory diseases. While
very rare, these monogenic diseases taught us much about the
molecular pathophysiology of more common forms of SLE, and
immune promoting, and amplifying effects of type I interferons
that (other than in primary type I interferonopathies) can also
be the result of tissue damage and immune complex formation.
Thus, primary and secondary (as a result of tissue damage, etc.)
type I IFN expression represents a strong link between innate
and adaptive immune responses in the “archetypal autoimmune
disease” SLE (4).
The pathophysiology of SLE is incompletely understood,
but strong evidence indicates the involvement of
epigenetic alterations in effector lymphocyte generation,
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FIGURE 4 | Epigenetic mechanisms contribute to dysregulation of innate and adaptive immune responses in SLE. Reduced CpG DNA methylation at IL10 and IL13
regulatory regions allow for increased gene expression. STAT3 recruits to IL10 regulatory elements in the proximal promoter and an intrinsic enhancer. At these
elements, STAT3 co-recruits the transcriptional co-activator p300 which has histone acetylase activity and supports chromatin decompaction through H3K18ac and
increased gene expression. Increased IL-10 expression in T cells promotes B cell activity in SLE, while not affecting effector T cells (likely due to reduced IL-10
receptor expression on T cells from SLE patients). The transcription factor cAMP response element mediator (CREM)α promotes effector T cells in SLE. It induces
H3K18 acetylation and CpG DNA demethylation across the IL17 gene cluster while recruiting DNMT3 to the IL2 locus instructing DNA methylation. Furthermore,
CREMα co-recruits histone deacetylase (HDAC)1 to the IL2 gene, which results in decreased H3K18ac and stable gene silencing. Furthermore, B and T cells are
stimulated by increased type I IFN (IFN-α and –β) expression in dendritic cells and neutrophils. Neutrophils exhibit reduced CpG DNA methylation of type I IFNs and
associated genes. Dendritic cells are primed for type I IFN release through stimulation of endosomal TLR9 through augmented NETosis of neutrophils. Neutrophils
from SLE patients release hypomethylated DNA, which binds to TLR9 more potently when compared to methylated DNA.
dysregulated cytokine expression and tissue damage in
SLE (see Figure 4).
Epigenetic Mechanisms Promoting
Effector Lymphocytes
Epigenetic alterations have been implicated with immune cell
function in SLE. First data on the involvement of epigenetic
events in SLE were generated investigating DNA methylation
(102). The likely strongest evidence for a causative role of DNA
methylation in SLE comes from the direct comparison of PBMCs
from genetically identical monozygotic twins discordant for
the development of SLE, which revealed 49 regions exhibiting
DNA hypomethylation in SLE patients when compared to their
healthy twin (103). Explanations for decreased DNAmethylation
observed in immune cells from SLE patients are manifold
and depend on environmental factors (UV exposure, viral
infections, etc.), individual factors (genetic predisposition, age,
and related enzyme activity, diet, etc.), genes investigated (hyper-
vs. hypo-methylation, etc.), medication (e.g., disease-modifying
antirheumatic drugs affect DNA methylation), etc. (8, 17, 104).
Effector and regulatory cytokines play a central role during
immune homeostasis, lymphocyte priming, and activation.
Indeed, a small study in patients with SLE refractory to standard
treatment showed beneficial effects of IL-10 blocking antibodies
(105). These effects have been attributed to immune activating
effects of IL-10, which are involved in B cell differentiation,
activation, immune globulin class switch, and the induction
of immunoglobulin production (106). Indeed, IL-10 and the
immune regulatory cytokine IL-13 can be measured at increased
levels in the serum of SLE patients and correlate with disease
activity. Increased cytokine expression was linked to DNA
hypomethylation at the promoter regions of the IL10 and
IL13 genes in CD4+ T cells (107). We investigated IL-10
mRNA expression in T cells from SLE patients, which was
increased compared to healthy controls and correlated with
disease activity. In agreement with aforementioned reports, the
IL10 promoter and in addition to this an intronic enhancer
element are methylated at reduced levels in patients when
compared to controls. This allows for STAT family transcription
factor binding, namely STAT3 and STAT5 recruitment. In
stimulated T cells from SLE patients, the activation of
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both elements is primarily conducted through STAT3 which
replaces STAT5 at the intronic enhancer. In T cells from
SLE patients STAT3 shows increased phosphorylation when
compared to controls which may explain elevated recruitment
to the DNA and replacement of STAT5. Furthermore, STAT
proteins co-recruit the transcriptional co-activator p300 that
has histone acetylase activity and confers H3K18ac at the
promoter and intronic enhancer further promoting IL-10
expression (108).
Imbalanced expression of the immune regulatory cytokine IL-
2 and the effector cytokine IL-17A have been centrally implicated
in the pathophysiology and accrual of tissue damage in SLE. In
addition to its immune promoting effects, IL-2 is required for
regulatory T cell functions, and reduced IL-2 expression (as in
SLE) promoted effector phenotypes (26, 109). Indeed, effector T
cells are the main source of IL-17A. Altered expression of IL-2
and increased expression of IL-17A in SLE have been linked with
impaired CpG DNA methylation and histone modifications in T
cells from SLE patients (26, 110, 111). The transcription factor
cyclic adenosine-mono-phosphate (cAMP) response element
regulator (CREM)α is expressed at increased levels in T cells
from patients with SLE, positively correlates with disease activity
and centrally contributed to effector T cell generation and
altered cytokine expression (110). CREMα co-recruits DNMT3
to the IL2 gene resulting in CpG DNA methylation and at
the same time induces DNA demethylation of IL17A in a
yet to be determined manner. Of note, the CREM promoter
itself is regulated by CpG DNA methylation and subject to
DNA demethylation in T cells from SLE patients. Furthermore,
CREMα is involved in orchestrating histone modifications in
effector T cells. CD4+ T cells from SLE patients are characterized
by increased H3K27me3 and decreased H3K18ac levels at the
IL2 promoter region as compared to healthy controls (26),
which is (at least partially) mediated by the interaction between
CREMα and HDAC1 at the IL2 but not the IL17A promoter.
Why CREMα interacts with variable epigenetic modifiers at
individual promoter regions remains unknown, but the overall
transcription factor environment may be involved in differential
“epigenetic effects” mediated by CREMα (17). In addition to
CD4+ effector T cells, CD4−CD8−TCR+CD3+ DN T cells
are involved in the pathophysiology of SLE and characterized
by high levels of IL-17A expression. DN T cells are involved
in tissue damage and infiltrate the kidneys of SLE patients
(112). CREMα is also centrally involved in the generation of
effector DN T cells from previously CD8+ T cells through the
down-regulation of CD8 co-receptor expression. Throughout
the CD8 cluster, CREMα co-recruits DNMT3 and histone
methyltransferase G9a to regulatory regions which induces stable
epigenetic silencing (77).
The most common organ complication of SLE is lupus
nephritis, which can result in significant tissue damage and
organ failure. The expression of miRNAs in PBMCs has been
tested for its suitability as biomarker to discriminate between
SLE and healthy controls, but also between active and inactive
or absent lupus nephritis (113). Selected miRNAs exhibited
strong differences between groups with the only limitation that
subclasses of lupus nephritis could not be differentiated. The
two most significantly upregulated miRNAs were miR-21 and
miR-155. Of note, miR-21 was also found in psoriasis lesions
(see above) and suggested to increase T cell survival in mice
(93). Furthermore, miR-21 promotes activated T cell phenotypes
(increased CD40L expression) and B cell differentiation through
increased IL-10 expression, which also results in increased
immunoglobulin production (see above). One of the targets of
miR-21 is the regulatory molecule programmed cell death 4,
which is encoded by PDCD4 gene and proposed to downregulate
IL-10 expression. Thus, increased miR-21 expression in SLE may
resemble another contributor to previously discussed increased
IL-10 levels (114). The second target identified, miR-155, can
contribute to increased inflammasome activation as found in
the context of psoriasis (above) through enhanced expression of
NLRP3 and caspase-1 (98), thus reflecting another example for
the coexistence and interconnection of autoinflammatory and
autoimmune mechanisms in SLE. Furthermore, kidney biopsies
allow comparison of epigenetic events in affected renal tissue and
show downregulation of miR-23b and upregulation of miR-146a
when compared to unaffected renal tissue from patients with
kidney cancer (115). Differential miRNA expression may be the
result on increased IL-17A tissue levels, since IL-17 expression
mediates reduced miR-23b and increased miR-146a expression
in murine fibroblasts. In HeLa cells, miR-23b inhibits IL-17A
expression. Thus, miR-23b and IL-17A appear to control one
another in a negative feedback loop, and reduced miR-23b levels
observed in lesions may prohibit recovery. Furthermore, miR-
23 suppresses NFκB activation in response to TNF-α and IL-
1β through downregulation of TGF-Beta-Activated Kinase 1-
Binding Protein (TAB)2, TAB3 and inhibitory κB kinase α (115).
This makes miR-23 another example for closely connected innate
and adaptive immunemechanisms regulated by epigenetic events
in SLE.
Epigenetic Regulation of the Innate
Immune System and Type I IFN Signature
In recent years, extensive research has been undertaken focusing
on type I interferons (IFN-α and IFN-β) and downstream IFN-
induced gene signatures in SLE (116–118). Approximately 50%
of SLE patients exhibit a type I IFN-induced gene signature
in PBMCs (119), and patients with more highly elevated type
I IFN-induced gene expression tend to have more severe
disease manifestations, including renal, CNS and/or hematologic
involvement (119). In juvenile-onset SLE patients, a pronounced
type I IFN signature is present even more frequently when
compared to cohorts with adult-onset disease (116). Type I IFN
expression in SLE patients has been linked with the activation
of plasmacytoid dendritic cells (pDCs) (120) and the presence
of low-density granulocytes (LDG) (116). Since type I IFNs are
potent inducers of adaptive immune responses and lymphocyte
maturation and differentiation, type I IFN signatures represent a
strong connection between innate and adaptive mechanisms in
SLE (121).
Epigenetic events have been implicated in the increased
expression of type I IFNs and associated genes. An epigenome-
wide association study investigating PBMCs from SLE
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patients in comparison to healthy controls found 85% of
differentially methylated genes to exhibit reduced CpG DNA
methylation supporting findings from other studies describing
low methylation levels in SLE (122). A number of genes with
reduced DNA methylation were type I IFN-induced genes
linking epigenetic patterns with gene expression signatures.
Similar findings were reported by others, demonstrating reduced
DNA methylation, and increased mRNA expression of type
I IFN associated genes in B cells, T cells, monocytes and
granulocytes (16). Reduced CpG DNA methylation of type I IFN
associated genes is (expectedly) also present in juvenile-onset
SLE (123) and contributes to increased type I IFN-induced
gene expression patterns (116). Neutrophils, which exhibit
even higher IFN-induced gene signatures as compared to other
leukocytes (117), have 68% of their CpG sites hypomethylated
and 32% hypermethylated (124). Within the hypomethylated
genes, several of the most significant ones were related to
type I IFN-induced genes. Interestingly, the DNA methylome
of LDG was identical to the methylation pattern observed in
autologous normal-density granulocytes (124), suggesting that
a combination of DNA methylation and additional mechanisms
may be responsible for further increased gene expression.
LDGs specifically have been described to produce neutrophil
extracellular traps (NETs) which lead to type I IFN release
(125, 126). Since hypomethylated DNA has an increased binding
capacity to TLR9 in endosomes resulting in the induction
of type I interferon expression, this amplification loop may
be central for maintenance of systemic inflammation in SLE
(2, 127). As briefly mentioned above, several mechanisms are
involved in reduced DNAmethylation in immune cells from SLE
patients, and include reduced activity of MAPK that contributes
to reduced activity of DNMTs (128, 129). Furthermore,
miRNAs have been demonstrated to negatively affect DNMTs
expression in CD4+ T cells from SLE patients (130) linking two
epigenetic events.
Upregulation of miR-126 and miR-29b in SLE patients
contribute to decrease in protein levels of DNMT1 (130).
miRNAs also affect type I IFN signaling in PBMCs: miR-
146a is expressed at reduced levels in SLE patients which
correlates with high disease activity, increased IFN scores,
and proteinuria (131). Furthermore, forced expression
of miR-146 reduces type I IFN induced gene expression.
However, the exact underlying mechanisms and target genes
remain unclear.
Taken together, the identification of a type I IFN signature
in a subset of SLE patients with active disease delivered new
mechanisms of amplification of inflammation. However, it
currently remains unclear whether this is a primary event or
rather the result of systemic inflammation and tissue damage.
Indeed, it appears likely that type I IFN expression is the primary
and disease-causing event only in a small subset of SLE patients
with monogenic disease (namely type I interferonopathies) (4).
However, it is accepted that type I interferons contribute to
the maintenance and even amplify systemic inflammation and
therefore may be target for therapeutic interventions. Since
epigenetic events play a role in the uncontrolled expression of
type I IFNs in SLE, “epigenetic interventions” may be future tools
to modify disease activity and inflammation at least in a subset
of patients.
SUMMARY AND CONCLUSIONS
Epigenetic events play an impartially understood but central
role in the pathophysiology of autoimmune/inflammatory
conditions. The largest body of evidence exists for CpG DNA
methylation, followed by histone modifications and non-
coding RNAs. However, we are currently only beginning to
understand that and by which mechanisms epigenetic events
contribute to disease. Completely deciphering epigenetic
contributors to disease is complicated by the fact that epigenetic
events are highly complex and work in combination with
other epigenetic marks, they are reversible and depend on
multiple variables, including cell cycle, and external factors
including the immunological micro-environment. While for
some epigenetic modifications underlying causes and their
involvement in the pathophysiology have been accepted, other
modifications may be the result of ongoing inflammation and
a secondary event in systemic autoimmune/inflammatory
disease. Nonetheless, secondary epigenetic modifications can
still alter inflammatory responses and therapeutic targeting of
these may help to control inflammation and tissue damage.
However, other than in cancer medicine, “epigenetic treatments”
currently remain “science fiction” in the field of immunology
and rheumatology, since target-directed applications are
currently not available, epigenetic changes are complex, and
untargeted approaches are associated with genome-wide
changes that may cause significant side-effects or even worsen
disease. Thus, future research is warranted to generate a
more complete understanding of epigenetic contributors to
inflammation and immune dysregulation, as well as their
underlying molecular causes. Only a full picture of epigenetics
in systemic inflammation will help us to (i) understand
the exact pathophysiology of autoimmune/inflammatory
conditions, (ii) deliver molecular causes for variable clinical
pictures, disease severity, and outcomes in related individuals
with phenotypically variable disease, and (iii) offer new
targets in the search for biomarkers and individualized and
target-directed treatments.
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